These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 26472579

  • 1. Lorcaserin Hcl for the treatment of obesity.
    Shukla AP, Kumar RB, Aronne LJ.
    Expert Opin Pharmacother; 2015; 16(16):2531-8. PubMed ID: 26472579
    [Abstract] [Full Text] [Related]

  • 2. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
    Bohula EA, Scirica BM, Fanola C, Inzucchi SE, Keech A, McGuire DK, Smith SR, Abrahamsen T, Francis BH, Miao W, Perdomo CA, Satlin A, Wiviott SD, Sabatine MS.
    Am Heart J; 2018 Aug; 202():39-48. PubMed ID: 29803985
    [Abstract] [Full Text] [Related]

  • 3. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
    Hurren KM, Berlie HD.
    Am J Health Syst Pharm; 2011 Nov 01; 68(21):2029-37. PubMed ID: 22011982
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
    Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, Anderson CM, BLOSSOM Clinical Trial Group.
    J Clin Endocrinol Metab; 2011 Oct 01; 96(10):3067-77. PubMed ID: 21795446
    [Abstract] [Full Text] [Related]

  • 7. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
    Nigro SC, Luon D, Baker WL.
    Curr Med Res Opin; 2013 Jul 01; 29(7):839-48. PubMed ID: 23574263
    [Abstract] [Full Text] [Related]

  • 8. Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists.
    Higgins GA, Zeeb FD, Fletcher PJ.
    J Psychopharmacol; 2017 Nov 01; 31(11):1403-1418. PubMed ID: 29072522
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
    Nguyen CT, Zhou S, Shanahan W, Fain R.
    Clin Ther; 2016 Jun 01; 38(6):1498-1509. PubMed ID: 27206567
    [Abstract] [Full Text] [Related]

  • 13. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.
    Higgins GA, Fletcher PJ, Shanahan WR.
    Pharmacol Ther; 2020 Jan 01; 205():107417. PubMed ID: 31629010
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
    Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM, CAMELLIA–TIMI 61 Steering Committee and Investigators.
    N Engl J Med; 2018 Sep 20; 379(12):1107-1117. PubMed ID: 30145941
    [Abstract] [Full Text] [Related]

  • 16. An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity.
    Tchang BG, Abel B, Zecca C, Saunders KH, Shukla AP.
    Expert Opin Pharmacother; 2020 Jan 20; 21(1):21-28. PubMed ID: 31693425
    [Abstract] [Full Text] [Related]

  • 17. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.
    Weissman NJ, Sanchez M, Koch GG, Smith SR, Shanahan WR, Anderson CM.
    Circ Cardiovasc Imaging; 2013 Jul 20; 6(4):560-7. PubMed ID: 23661689
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity.
    Hurren KM, Dunham MW.
    Expert Opin Drug Metab Toxicol; 2017 Aug 20; 13(8):891-896. PubMed ID: 28636828
    [Abstract] [Full Text] [Related]

  • 19. Multicenter, placebo-controlled trial of lorcaserin for weight management.
    Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR, Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group.
    N Engl J Med; 2010 Jul 15; 363(3):245-56. PubMed ID: 20647200
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of lorcaserin for the treatment of obesity.
    Berlie HD, Hurren KM.
    Expert Opin Drug Metab Toxicol; 2013 Aug 15; 9(8):1053-9. PubMed ID: 23802690
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.